Soligenix Announces Pricing of $7.5 Million Public Offering

PRINCETON, N.J. – Sept. 26, 2025 – Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical firm in its late stages of development, announced today the pricing details of a public offering aimed at boosting its financial resources. This offering, described as a “reasonable best efforts” endeavor, involves the sale of 5,555,560 shares of common stock (or equivalent securities) alongside warrants to purchase an equal number of shares.

The combined purchase price is set at $1.35 per share and accompanying warrant. These warrants provide the holder the right to purchase one share of common stock at an exercise price of $1.35, exercisable immediately and expiring five years from the date of issuance. This strategic financial maneuver is designed to fortify Soligenix’s position in the competitive biopharmaceutical landscape.

In a related move, Soligenix has also reached an agreement to amend existing warrants issued in May 2023, April 2024, and July 2024. These existing warrants, representing 1,162,064 shares of common stock, will now have a reduced exercise price of $1.35 per share and will expire on the same date as the warrants being sold in the public offering, aligning the terms of these securities.

The offering is expected to close around September 29, 2025, contingent upon meeting standard closing conditions. Soligenix anticipates gross proceeds of approximately $7.5 million from the offering, before deducting fees for the placement agent and other offering-related expenses.

The company plans to allocate the net proceeds from this offering strategically. A significant portion will be directed towards funding research and development initiatives, supporting commercialization activities, bolstering working capital, and addressing general corporate needs. This infusion of capital is particularly crucial for Soligenix as it seeks to advance its pipeline of treatments for rare diseases.

The choice of A.G.P./Alliance Global Partners as the sole placement agent underscores Soligenix’s intent to leverage established financial expertise to ensure the success of this capital raise. A.G.P.’s experience in the biopharmaceutical sector should prove valuable in navigating the complexities of the offering and maximizing its potential.

This public offering is being conducted under a registration statement on Form S-1 (File No. 333-290413) previously filed with the Securities and Exchange Commission (SEC) on September 19, 2025, and declared effective on September 25, 2025. The offering is being made through a prospectus that forms part of the effective registration statement. An electronic copy of the final prospectus may be obtained on the SEC’s website.

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor will there be any sale of these securities in any jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Soligenix

Soligenix is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases with unmet medical needs. Its Specialized BioTherapeutics segment is developing HyBryte™ (SGX301), a photodynamic therapy for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment includes vaccine programs for ricin toxin (RiVax®), filoviruses (Marburg and Ebola), and COVID-19 (CiVax™), utilizing the ThermoVax® heat stabilization platform.

Soligenix’s strategic focus on rare diseases, coupled with its innovative technology platforms like ThermoVax®, positions it for potential growth areas in the biopharmaceutical sector. However, like all companies in this industry, Soligenix faces regulatory hurdles, clinical trial risks, and the challenge of securing adequate funding to support its research and development programs. This public offering represents a critical step in securing the financial resources necessary to advance its pipeline and ultimately bring new treatments to patients in need.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including the potential market sizes, patient populations, clinical trial enrollment, the expected timing for closing the Offering, and the intended use of proceeds. Actual results may differ materially due to factors such as the success of clinical trials, regulatory approvals, funding availability, competition, and government regulations. Soligenix assumes no obligation to update these forward-looking statements.